Noninvasive screening with serum markers, or indicators in the blood, can identify patients at risk for liver fibrosis. Fibrotest, an indirect serum marker panel is the most widely used and validated serum marker panel used worldwide.
Ultrasound has been used for noninvasive investigation of liver, for detection of focal lesions, assessment the degree of liver fibrosis, description of thrombosis of the portal vein. FibroScan
or electrography imaging is helpful to assess the level of liver fibrosis or cirrhosis, to monitor the severity of disease to determine the treatment plan, and to diagnose complications in patients with cirrhosis